Full View

A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer

H Chow, PM Ghosh, R deVere White, CP Evans… - Cancer, 2016 - Wiley Online Library
BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
被引用次数：56 相关文章

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

H Chow, PM Ghosh, R deVere White, CP Evans… - Cancer, 2016 - europepmc.org
Background The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
[HTML] nih.gov

[HTML][HTML] A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

H Chow, PM Ghosh, RV White, CP Evans, MA Dall'Era… - Cancer, 2016 - ncbi.nlm.nih.gov
Background The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer

H Chow, PM Ghosh, RV White, CP Evans, MA Dall'Era… - Cancer, 2016 - infona.pl
BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

H Chow, CX Pan, M DallEra, S Yap, Y Li, L Beckett… - Cancer, 2016 - escholarship.org
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

H Chow, PM Ghosh, RV White, CP Evans… - Cancer, 2016 - pubmed.ncbi.nlm.nih.gov
Background The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

H Chow, PM Ghosh, R Devere White, CP Evans… - Cancer, 2016 - hero.epa.gov
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

H Chow, PM Ghosh, R deVere White, CP Evans… - Cancer, 2016 - escholarship.org
BackgroundThe mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …